AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. The company also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.
Follow-Up Questions
Who is the CEO of AstraZeneca PLC?
Mr. Pascal Soriot is the Chief Executive Officer of AstraZeneca PLC, joining the firm since 2012.
What is the price performance of AZNCF stock?
The current price of AZNCF is $163.67, it has decreased 0% in the last trading day.
What are the primary business themes or industries for AstraZeneca PLC?
AstraZeneca PLC belongs to Pharmaceuticals industry and the sector is Health Care
What is AstraZeneca PLC market cap?
AstraZeneca PLC's current market cap is $253.7B
Is AstraZeneca PLC a buy, sell, or hold?
According to wall street analysts, 28 analysts have made analyst ratings for AstraZeneca PLC, including 10 strong buy, 19 buy, 5 hold, 0 sell, and 10 strong sell
